Cognition Free Cash Flow Yield vs Ev To Free Cash Flow Analysis

CGTX Stock

USD 0.43 0 0.93%

Cognition Therapeutics financial indicator trend analysis is way more than just evaluating Cognition Therapeutics prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Cognition Therapeutics is a good investment. Please check the relationship between Cognition Therapeutics Free Cash Flow Yield and its Ev To Free Cash Flow accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cognition Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

For more information on how to buy Cognition Stock please use our How to Invest in Cognition Therapeutics guide.

Free Cash Flow Yield vs Ev To Free Cash Flow

Free Cash Flow Yield vs Ev To Free Cash Flow Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Cognition Therapeutics Free Cash Flow Yield account and Ev To Free Cash Flow. At this time, the significance of the direction appears to have pay attention.

The correlation between Cognition Therapeutics' Free Cash Flow Yield and Ev To Free Cash Flow is -0.91. Overlapping area represents the amount of variation of Free Cash Flow Yield that can explain the historical movement of Ev To Free Cash Flow in the same time period over historical financial statements of Cognition Therapeutics, assuming nothing else is changed. The correlation between historical values of Cognition Therapeutics' Free Cash Flow Yield and Ev To Free Cash Flow is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Free Cash Flow Yield of Cognition Therapeutics are associated (or correlated) with its Ev To Free Cash Flow. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Ev To Free Cash Flow has no effect on the direction of Free Cash Flow Yield i.e., Cognition Therapeutics' Free Cash Flow Yield and Ev To Free Cash Flow go up and down completely randomly.

Correlation Coefficient

-0.91

Relationship Direction	Negative
Relationship Strength	Significant

View All Relationships

Free Cash Flow Yield

A financial solvency ratio that compares the free cash flow per share a company is expected to earn against its market value per share, calculated as free cash flow per share divided by market price per share.

Ev To Free Cash Flow

A valuation metric comparing the company's enterprise value to its free cash flow, used to evaluate whether a company is undervalued or overvalued.

Most indicators from Cognition Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Cognition Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cognition Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

For more information on how to buy Cognition Stock please use our How to Invest in Cognition Therapeutics guide.Issuance Of Capital Stock is likely to rise to about 11.5 M in 2024, whereas Selling General Administrative is likely to drop slightly above 9.8 M in 2024.

	2021	2022	2023	2024 (projected)
Interest Expense	893K	28K	27K	25.7K
Depreciation And Amortization	93K	235K	252K	239.4K

Interest Expense Depreciation And Amortization

Cognition Therapeutics fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Long Term Debt	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Non Current Liabilities Total	Capital Lease Obligations	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Net Invested Capital	Property Plant And Equipment Gross
Total Assets		-0.83	0.89	0.88	0.98	0.78	0.95	0.54	0.07	-1.0	-0.78	0.94	1.0	0.59	0.78	1.0	-0.52	0.67	-0.94	0.67	0.91	0.61	0.87	-0.95	0.99	0.67
Short Long Term Debt Total	-0.83		-0.73	-0.87	-0.89	-0.49	-0.9	-0.64	-0.49	0.86	0.79	-0.89	-0.81	-0.57	-0.48	-0.81	0.24	-0.74	0.92	-0.73	-0.81	-0.66	-0.83	0.92	-0.88	-0.71
Other Current Liab	0.89	-0.73		0.96	0.92	0.94	0.93	0.61	0.09	-0.9	-0.89	0.91	0.9	0.47	0.93	0.9	-0.8	0.78	-0.92	0.72	0.96	0.76	0.92	-0.92	0.92	0.76
Total Current Liabilities	0.88	-0.87	0.96		0.94	0.84	0.96	0.74	0.34	-0.9	-0.91	0.93	0.88	0.58	0.83	0.88	-0.63	0.87	-0.96	0.81	0.95	0.81	0.97	-0.96	0.94	0.85
Total Stockholder Equity	0.98	-0.89	0.92	0.94		0.79	0.99	0.63	0.2	-0.99	-0.87	0.96	0.98	0.62	0.79	0.98	-0.55	0.76	-0.99	0.76	0.96	0.72	0.92	-0.99	1.0	0.75
Other Liab	0.78	-0.49	0.94	0.84	0.79		0.8	0.6	-0.02	-0.77	-0.81	0.73	0.8	0.5	1.0	0.8	-0.89	0.74	-0.78	0.69	0.88	0.74	0.85	-0.78	0.81	0.74
Net Tangible Assets	0.95	-0.9	0.93	0.96	0.99	0.8		0.66	0.26	-0.96	-0.92	0.96	0.95	0.6	0.8	0.95	-0.6	0.81	-1.0	0.8	0.98	0.79	0.93	-1.0	0.99	0.79
Property Plant And Equipment Net	0.54	-0.64	0.61	0.74	0.63	0.6	0.66		0.77	-0.53	-0.76	0.48	0.5	0.89	0.58	0.5	-0.3	0.95	-0.7	0.93	0.68	0.86	0.86	-0.67	0.62	0.98
Current Deferred Revenue	0.07	-0.49	0.09	0.34	0.2	-0.02	0.26	0.77		-0.08	-0.4	0.11	0.02	0.61	-0.04	0.02	0.23	0.65	-0.32	0.65	0.22	0.57	0.43	-0.29	0.18	0.65
Net Debt	-1.0	0.86	-0.9	-0.9	-0.99	-0.77	-0.96	-0.53	-0.08		0.8	-0.96	-1.0	-0.55	-0.77	-1.0	0.53	-0.67	0.95	-0.66	-0.92	-0.62	-0.87	0.97	-0.99	-0.66
Retained Earnings	-0.78	0.79	-0.89	-0.91	-0.87	-0.81	-0.92	-0.76	-0.4	0.8		-0.8	-0.77	-0.61	-0.8	-0.77	0.7	-0.92	0.93	-0.91	-0.96	-0.95	-0.91	0.91	-0.87	-0.87
Accounts Payable	0.94	-0.89	0.91	0.93	0.96	0.73	0.96	0.48	0.11	-0.96	-0.8		0.95	0.4	0.73	0.95	-0.55	0.65	-0.94	0.61	0.9	0.6	0.85	-0.96	0.96	0.63
Cash	1.0	-0.81	0.9	0.88	0.98	0.8	0.95	0.5	0.02	-1.0	-0.77	0.95		0.55	0.8	1.0	-0.56	0.64	-0.93	0.64	0.91	0.59	0.86	-0.95	0.98	0.65
Non Current Assets Total	0.59	-0.57	0.47	0.58	0.62	0.5	0.6	0.89	0.61	-0.55	-0.61	0.4	0.55		0.5	0.55	-0.13	0.79	-0.63	0.85	0.6	0.71	0.75	-0.62	0.62	0.85
Long Term Debt	0.78	-0.48	0.93	0.83	0.79	1.0	0.8	0.58	-0.04	-0.77	-0.8	0.73	0.8	0.5		0.8	-0.88	0.73	-0.78	0.67	0.87	0.72	0.84	-0.77	0.8	0.73
Cash And Short Term Investments	1.0	-0.81	0.9	0.88	0.98	0.8	0.95	0.5	0.02	-1.0	-0.77	0.95	1.0	0.55	0.8		-0.56	0.64	-0.93	0.64	0.91	0.59	0.86	-0.95	0.98	0.65
Net Receivables	-0.52	0.24	-0.8	-0.63	-0.55	-0.89	-0.6	-0.3	0.23	0.53	0.7	-0.55	-0.56	-0.13	-0.88	-0.56		-0.53	0.57	-0.47	-0.72	-0.62	-0.58	0.56	-0.57	-0.48
Common Stock Shares Outstanding	0.67	-0.74	0.78	0.87	0.76	0.74	0.81	0.95	0.65	-0.67	-0.92	0.65	0.64	0.79	0.73	0.64	-0.53		-0.84	0.98	0.85	0.96	0.93	-0.82	0.76	0.99
Non Current Liabilities Total	-0.94	0.92	-0.92	-0.96	-0.99	-0.78	-1.0	-0.7	-0.32	0.95	0.93	-0.94	-0.93	-0.63	-0.78	-0.93	0.57	-0.84		-0.83	-0.98	-0.81	-0.94	1.0	-0.98	-0.82
Capital Lease Obligations	0.67	-0.73	0.72	0.81	0.76	0.69	0.8	0.93	0.65	-0.66	-0.91	0.61	0.64	0.85	0.67	0.64	-0.47	0.98	-0.83		0.84	0.97	0.89	-0.81	0.76	0.97
Inventory	0.91	-0.81	0.96	0.95	0.96	0.88	0.98	0.68	0.22	-0.92	-0.96	0.9	0.91	0.6	0.87	0.91	-0.72	0.85	-0.98	0.84		0.86	0.93	-0.97	0.96	0.82
Other Current Assets	0.61	-0.66	0.76	0.81	0.72	0.74	0.79	0.86	0.57	-0.62	-0.95	0.6	0.59	0.71	0.72	0.59	-0.62	0.96	-0.81	0.97	0.86		0.86	-0.78	0.72	0.92
Other Stockholder Equity	0.87	-0.83	0.92	0.97	0.92	0.85	0.93	0.86	0.43	-0.87	-0.91	0.85	0.86	0.75	0.84	0.86	-0.58	0.93	-0.94	0.89	0.93	0.86		-0.94	0.92	0.94
Total Liab	-0.95	0.92	-0.92	-0.96	-0.99	-0.78	-1.0	-0.67	-0.29	0.97	0.91	-0.96	-0.95	-0.62	-0.77	-0.95	0.56	-0.82	1.0	-0.81	-0.97	-0.78	-0.94		-0.99	-0.8
Net Invested Capital	0.99	-0.88	0.92	0.94	1.0	0.81	0.99	0.62	0.18	-0.99	-0.87	0.96	0.98	0.62	0.8	0.98	-0.57	0.76	-0.98	0.76	0.96	0.72	0.92	-0.99		0.75
Property Plant And Equipment Gross	0.67	-0.71	0.76	0.85	0.75	0.74	0.79	0.98	0.65	-0.66	-0.87	0.63	0.65	0.85	0.73	0.65	-0.48	0.99	-0.82	0.97	0.82	0.92	0.94	-0.8	0.75

Click cells to compare fundamentals

Cognition Therapeutics Account Relationship Matchups

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

C	Citigroup
GM	General Motors
F	Ford Motor

Additional Tools for Cognition Stock Analysis

When running Cognition Therapeutics' price analysis, check to measure Cognition Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cognition Therapeutics is operating at the current time. Most of Cognition Therapeutics' value examination focuses on studying past and present price action to predict the probability of Cognition Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cognition Therapeutics' price. Additionally, you may evaluate how the addition of Cognition Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Cognition Free Cash Flow Yield vs Ev To Free Cash Flow Analysis

Free Cash Flow Yield vs Ev To Free Cash Flow

Free Cash Flow Yield vs Ev To Free Cash Flow Correlation Analysis

Correlation Coefficient

Free Cash Flow Yield

Ev To Free Cash Flow

Cognition Therapeutics fundamental ratios Correlations

Cognition Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Also Currently Popular

Additional Tools for Cognition Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Total Assets
Net Invested Capital	+ 1.0	Total Stockholder Equity
Long Term Debt	+ 1.0	Other Liab
Cash And Short Term Investments	+ 1.0	Cash
Total Liab	+ 1.0	Non Current Liabilities Total

Cash And Short Term Investments	- 1.0	Net Debt
Cash	- 1.0	Net Debt
Total Liab	- 1.0	Net Tangible Assets
Non Current Liabilities Total	- 1.0	Net Tangible Assets
Net Debt	- 1.0	Total Assets
Net Invested Capital	- 0.99	Total Liab